Neoplasms

All Conditions

Digestive System Diseases

Gland and Hormone Related Diseases

Rare Diseases

Carcinoma

Neuroendocrine Tumors

Carcinoma, Neuroendocrine

Carcinoid Tumor

Apudoma

Adenoma

Adenoma, Islet Cell

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Pancreatic Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Neuroendocrine Tumor

Pancreatic Neuroendocrine Tumor

Neuroepithelioma

Pancreatic Cancer

We will perform 68Ga-DOTATATE PET scans on subjects.

68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.

Richard J. Campeau, M.D.

Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine tumors. Patients with neuroendocrine tumors will be imaged with this agent and it will be compared to conventional imaging methods to determine the safety and efficacy of this radiopharmaceutical.

68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

Ochsner Health System

Professor of Radiology and Internal Medicine

Hematinics

All Drugs and Chemicals

Liver Extracts

Patients will receive a 68Ga-DOTATATE PET scans

68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography (PET). Efficacy of the 68Ga-DOTATATE PET scan was assessed and compared to 111In-Pentetreotide scan and to scans with CT and/or MRI. Safety and toxicity were also assessed with pre-injection and post-imaging vital signs, pulse oximetry on room air, 12 lead ECGs, and blood laboratory tests, including tumor markers, liver and renal functions and blood counts, and direct patient questioning. Late delayed tumor markers, liver and renal functions and blood counts were assessed when available.

68Ga-DOTATATE PET scan

Ronald C. Walker, MD

Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET scan is a new generation of scans that might have improved sensitivity and resolution specifically for neuroendocrine tumors. The investigators will scan people with this cancer and compare it to other conventional imaging methods to see if it improves patient care.

Eligible participants will undergo baseline assessments at enrollment. Study participants will receive a one-time administration of 68GaDOTATATE and undergo a PET/CT imaging study. Scans will be performed with "negative" oral contrast (e.g. Volumen™ or equivalent), as many NETs involve the GI tract.

68Ga-DOTATATE PET Scan in Neuroendocrine Cancer

Use of 68Ga-DOTATATE PET Scanning for Diagnosis and Treatment of Metastatic Neuroendocrine Tumors

Data are primarily imaging data and toxicity data submitted for peer-review publication and US FDA review, but not shared with a public data archive.

Determine if the 68Ga-DOTATATE PET scan changes patient care plans compared to conventional imaging/diagnostic techniques (Octreoscan, MRI, CT, U/S).

Determine if any adverse effects are associated with the 68Ga-DOTATATE PET scan and the number of patients that experience them using NCI Common Terminology Criteria for Adverse Events v4.0, where: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening; Grade 5, death. Toxicities present at baseline and continuing without change in grade were excluded for assessment of this outcome measure.

Vanderbilt-Ingram Cancer Center

Professor of Clinical Radiology

Toxicity data were compiled and individual patient test results pre-and-post-scans were compared. Non-systematic assessment was used for patients with limited long term follow-up.

Patients will receive 68Ga-DOTATATE PET scans. 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.

68Ga-DOTATATE PET Scan

68Ga-DOTATATE PET scans performed on subjects. 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.

Imaging/Scans

Age, Continuous

Sex: Female, Male

United States

Region of Enrollment

patients with known or suspected pulmonary or gastroenteropancreatic (GEP) neuroendocrine tumors (NETS)

Long term follow-up of lab values was limited in some patients who lived outside the local region.

Dr. Ronald Walker

68Ga-DOTATATE PET scan will be administered to patients in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.

68Ga-DOTATATE PET

Number of Severe Adverse Events Occurences Resulting in Changes to Patient Treatment Plans, as a Measure of Safety and Tolerability

Patients experienced a major change

Patients experienced a minor change

Patients experienced no change

68Ga-DOTATATE will be administered to patient in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.

A major change in management is defined as:planned surgery cancelled, added, or a different type of surgery was planned, or a medication was added or stopped, or a new treatment modality (e.g. radiation) was added. A minor change was adjustment to planned surgery or radiation field, or in current medication dosage.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors	NCT02038738	Neuroendocrine Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoid Carcinoid Tumor Islet Cell Tumo... Apudoma	68Ga-DOTATATE w...	18 Years -	Ochsner Health System
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors	NCT02038738	Neuroendocrine Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoid Carcinoid Tumor Islet Cell Tumo... Apudoma	68Ga-DOTATATE w...	18 Years -	Ochsner Health System
68Ga-DOTATATE PET Scan in Neuroendocrine Cancer	NCT01396382	Neuroendocrine ...	68Ga-DOTATATE P...	18 Years -	Vanderbilt-Ingram Cancer Center

Spots Global Cancer Trial Database for gallium

Every month we try and update this database with for gallium cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for gallium

Every month we try and update this database with for gallium cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for gallium cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.